Suzhou Innovent Bio acquired China rights to an atopic dermatitis therapy developed by Denmark 's Union Therapeutics in a $267 million agreement. Innovent will pay $20 million upfront and make up to $247 million in milestones, plus royalties. The candidate, orismilast, is a next-gen PDE4 inhibitor with broad anti-inflammatory properties that has shown positive proof of concept data orally in psoriasis and topically in atopic dermatitis. Orismilast is being developed as a best- or first-in-class treatment option in both diseases. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //